Impact Biomedical approves 1-for-12.62 reverse stock split ahead of proposed Zoar merger
Impact Biomedical announced a 1-for-12.62 reverse stock split effective Sept. 23, 2026 to support its proposed merger with Zoar Limited and NYSE American continued-listing objectives.Key Highlights:Original SEC Filing: IMPACT BIOMEDICAL INC. [ IBO ] - 8-K - Sep. 14, 2026This is an AI-powered summar…